A5053049998- Multiple Sclerosis Research Studies
- Acute Lymphoblastic Leukemia research
- Autoimmune and Inflammatory Disorders Research
- Immunotherapy and Immune Responses
- Rheumatoid Arthritis Research and Therapies
Karolinska Institutet
2021-2025
Karolinska University Hospital
2025
Abstract Background and purpose Rituximab (RTX) is frequently used off‐label in multiple sclerosis. However, studies on the risk–benefit profile of RTX pediatric‐onset sclerosis are scarce. Methods In this multicenter retrospective cohort study, patients with from Sweden, Austria Germany, who received treatment were identified by chart review. Annualized relapse rates, Expanded Disability Status Scale scores magnetic resonance imaging parameters (new T2 lesions contrast‐enhancing lesions)...
Few controlled trials of disease-modifying therapies (DMTs) have been conducted on the pediatric-onset multiple sclerosis (PoMS) population, leading to extensive off-label use approved only for adults. This highlights need real-world evidence guide clinical practice. Clinical registries can offer high-quality data, but limitations such as missing and erroneous information must be considered. validation study compared Swedish Multiple Sclerosis registry data from 122 PoMS patients medical...
Abstract Background and purpose Pediatric‐onset multiple sclerosis (PoMS) is associated with high health care use. To plan resource allocation for this patient group, knowledge of the incidence rate prevalence important. However, such studies are scarce, few population‐based, methodology varies widely. We aimed to address gap by performing a nationwide study PoMS in Sweden, an area (MS) prevalence. Methods MS cases were identified linking two registers, National Patient Register Swedish...